Research
Hormonal
Erectile dysfunction (ED) affects up to three out of four individuals with diabetes.
Healthcare providers should be aware of the high prevalence of ED in diabetic patients.
StrongSupportsmedium confidence
Erectile dysfunction (ED) is a common yet frequently underrecognized microvascular complication of diabetes, affecting up to three out of four individuals.
Why this rating
The claim is based on a broad observation of a common condition in a specific population.
Source
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Dimitris Kounatidis et al. · Biomolecules · 2025
DOI 10.3390/biom15091284
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →